Cytek Biosciences Gets Approval for Clinical Use of TBNK Reagents in China-May 2024-www.financetom.com

Cytek Biosciences Gets Approval for Clinical Use of TBNK Reagents in China

News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities

Cytek Biosciences Gets Approval for Clinical Use of TBNK Reagents in China

May 28, 2024 3:29 PM

06:01 PM EDT, 05/28/2024 (MT Newswires) -- Cytek Biosciences ( CTKB ) said Tuesday it received approval from China's National Medical Products Administration for the clinical diagnostic use of its 1-laser and 2-laser 6-color TBNK reagent cocktails in hospitals, laboratories and clinics.

The TBNK reagents help in diagnosing and monitoring various immune-related conditions, including immunodeficiencies, autoimmune diseases, infectious diseases and cancers.

Previous page： Allogene Therapeutics Q4 Loss Narrows, Revenue Drops Next page： Looking At Amgen's Recent Unusual Options Activity

Comments

Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.

Show More Comments

Related Articles >

Allogene Therapeutics Q4 Loss Narrows, Revenue Drops

Mar 14, 2024

04:31 PM EDT, 03/14/2024 (MT Newswires) -- Allogene Therapeutics ( ALLO ) reported late Thursday a Q4 net loss of $0.51 per diluted share, narrowing from $0.67 a year ago. Analysts polled by Capital IQ expected a loss of $0.45. Collaboration revenue for the quarter ended Dec. 31 was $21,000, compared with $26,000 a year earlier. Analysts surveyed by Capital...

Looking At Amgen's Recent Unusual Options Activity

Mar 14, 2024

Financial giants have made a conspicuous bearish move on Amgen ( AMGN ). Our analysis of options history for Amgen ( AMGN ) revealed 11 unusual trades. Delving into the details, we found 36% of traders were bullish, while 63% showed bearish tendencies. Out of all the trades we spotted, 9 were puts, with a value of $445,336, and 2...

EverCommerce Q4 Loss Widens, Revenue Rises; Q1, 2024 Revenue Outlook Set; Shares Drop After Hours

Mar 14, 2024

04:28 PM EDT, 03/14/2024 (MT Newswires) -- EverCommerce ( EVCM ) reported a Q4 loss late Thursday of $0.12 per diluted share, widening from the loss of $0.09 a year earlier. Analysts polled by Capital IQ expected a loss of $0.02. Revenue in the quarter ended Dec. 31 rose to $169.4 million from $161.8 million a year earlier. Analysts surveyed...

Blink Charging Q4 Earnings: Revenue and EPS Beat, Strong FY24 Outlook and More

Mar 14, 2024

Blink Charging Co. ( BLNK ) reported its fourth-quarter financial results after the bell Thursday. Here's a look at the highlights. Blink reported quarterly losses of 28 cents per share, which beat the analyst consensus estimate of losses of 31 cents and represented a 31.71% increase year-over-year. The company clocked fourth-quarter sales of $42.71 million, beating the analyst consensus estimate of $35.64...